MELDONIUM: EFFECTIVE ACTION POINTS
https://doi.org/10.15829/1728-8800-2013-2-94-97
Abstract
The paper is focused on hypoxia and cell ischemia as universal pathogenetic mechanisms of disease development, which can be addressed by both etiotropic and pathogenetic therapy. The latter is represented by the so-called metabolic correctors. At present, one of the most widely used metabolic correctors is mildronate. The authors discuss the effectiveness of mildronate in various clinical situations and also present the relevant original findings.
About the Authors
A. L. Vertkin
A. I. Evdokimov Moscow State Medico-Stomatological University, Moscow
Russian Federation
Russian Federation
N. O. Khovasova
A. I. Evdokimov Moscow State Medico-Stomatological University, Moscow
Russian Federation
Russian Federation
V. V. Pshenichnikova
A. I. Evdokimov Moscow State Medico-Stomatological University, Moscow
Russian Federation
Russian Federation
M. A. Alekseev
A. I. Evdokimov Moscow State Medico-Stomatological University, Moscow
Russian Federation
Russian Federation
A. U. Abdullaeva
A. I. Evdokimov Moscow State Medico-Stomatological University, Moscow
Russian Federation
Russian Federation
References
1. Kalvin’sh IJa. Mildronat: mechanism of action and prospects for its application. Riga: Grindeks 2002; 112 р. Russian (Калвиньш И. Я. Милдронат: механизм действия и перспективы его применения. Рига: Гриндекс 2002; 112 с).
2. Eastaugh J, Calvert M., Freemantle N. Ighlighting the need for better patient care instable angina: results of the international Angina Treatment Patterns (ATP) Survey in 7074 patients. Fam Pract 2005; 22 (1): 43–50.
3. Dambrova M, Dajja D, Liepin’sh Je, et al. Biochemical mechanisms of action of mildronat in ischemic stress. Vrachebnoe delo 2004; 2: 68–74. Russian (Дамброва М., Дайя Д., Лиепиньш Э. и др. Биохимические механизмы действия милдроната в условиях ишемического стресса. Врачебное дело 2004; 2: 68–74).
4. Makolkin VI, Osadchij KK. The role of myocardial cyto-protection in optimizing the treatment of coronary heart disease. Cons Med 2004; 5: 304–7. Russian (Маколкин В. И., Осадчий К. К. Роль миокардиальной цитопротекции в оптимизации лечения ишемической болезни сердца. Cons Med 2004; 5: 304–7).
5. Stacenko ME, Belenkova SV, Sporova OE, et al. The effectiveness of the treatment of chronic heart failure in patients with type 2 diabetes in early post infarction period. Biomedicina 2006; 3: 67–9. Russian (Стаценко М. Е., Беленкова С. В., Спорова О. Е. и др. Эффективность лечения хронической сердечной недостаточности у больных с сахарным диабетом типа 2 в раннем постинфарктном периоде. Биомедицина 2006; 3: 67–9).
6. Hlebodarov FE, Mihin VP. The role of cyto-protectors in the treatment of patients with arterial hypertension in the face of enalapril therapy. Russian journal of cardiology 2009; 5: 1–5. Russian (Хлебодаров Ф. Е., Михин В. П. Роль цитопротекторов в лечении больных артериальной гипертонией на фоне терапии эналаприлом. Российский кардиологи ческий журнал 2009; 5: 1–5).
7. Groot V, Beckerman H, Lankhorst GJ, et al. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 2003; 56 (3): 221–9.
8. Fortin M, Bravo G, Hudon C, et al. Prevalence of multimorbidity among adults seen in family practice. Ann Fam Med 2005; 3: 223–8.
9. Chronic diseases and associated risk factors in Australia: Australian Institute of Health and Welfare (AIHW). http://www.aihw.gov.au/ publications/index.cfm/title/10319.с
Review
For citations:
Vertkin A.L., Khovasova N.O., Pshenichnikova V.V., Alekseev M.A., Abdullaeva A.U. MELDONIUM: EFFECTIVE ACTION POINTS. Cardiovascular Therapy and Prevention. 2013;12(2):94-97. (In Russ.) https://doi.org/10.15829/1728-8800-2013-2-94-97
Views:
2268
Email this article 
